Christine MacArelli
Rare Disease Account Manager @Kalvista Pharmaceuticals, Inc
Signup · Get unlimited contacts
WORK HISTORY
Rare Disease Account Manager @Kalvista Pharmaceuticals, Inc
As a Rare Disease Account Manager at KalVista Pharmaceuticals, I am responsible for the launch of Ekterly, a novel oral plasma kallikrein inhibitor for the treatment of acute hereditary angioedema (HAE) attacks throughout Upstate New York and Connecticut. Partner with allergists, immunologists, and key healthcare stakeholders to ensure timely access to therapy and optimal patient outcomes.• Drove a successful launch in an emerging biotech environment, accelerating provider adoption and delivering strong national performance in the launch quarter. • Built disease awareness and pre-launch activation by engaging priority allergists, immunologists,and regional networks—ensuring targeted, high-impact provider education.• Established partnerships with leading allergists and immunology networks to streamline access andreimbursement.• Collaborated cross-functionally with Market Access, Medical Affairs, and Patient Services to drivetreatment adoption and adherence.
EDUCATION
University at Albany
B.S., Human Biology
ABOUT CHRISTINE MACARELLI
As a Rare Disease Account Manager at KalVista Pharmaceuticals, I am responsible for the launch of Ekterly, a novel oral plasma kallikrein inhibitor for the treatment of acute hereditary angioedema (HAE) attacks throughout Upstate New York and Connecticut. I am driven by my passion for advancing innovative therapies for rare diseases and educating healthcare providers and patients on the benefits and challenges of emerging treatments.With over 20 years of industry experience and a B.S. in Human Biology, I leverage my clinical medicine knowledge and customer relationship management skills to deliver exceptional results. My background includes successfully launching Daybue, a first-in-class therapy for Rett Syndrome, across New England while at Acadia Pharmaceuticals. In this role, I engaged with pediatric and adult neurologists, geneticists, and developmental pediatricians at academic institutions, using my rare disease launch expertise and a patient-first mindset.Previously, I launched Vyvgart, a rare disease IV drug for generalized myasthenia gravis, in the Albany, NY territory, where I exceeded sales quotas, achieved territory growth, and ranked among the top performers in the region and nation. I am proud to continue bringing hope and solutions to patients with rare and complex conditions.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.